Fidelity
Home > Boards > US Listed > Biotechs >

Intellicell Biosciences, Inc. (SVFC)

SVFC RSS Feed
Add SVFC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigBadWolf, Gannicus, cazual, phithebuilder, deepandlong, canitocano73
Search This Board:
Last Post: 4/18/2014 2:06:14 AM - Followers: 541 - Board type: Free - Posts Today: 3

 



SHARE STRUCTURE:

SHARES OUTSTANDING:

1,369,825,849 a/o January 28, 2014 (per latest filing)


AUTHORIZED SHARES:
3,500,000,000


Preferred Shares
1,000,000 (held by CEO) with 1 to 1000 conversion rate

http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=QeV5YJsrjGxDwCHWzDnw6A%253d%253d&nt7=0





$$SVFC where the money has gone, with quotes, links to filings w/ page numbers & Steven Victor's signature attesting to it all...for complete verification

Quote:
Net cash used in operating activities

Net cash used in operating activities was $1,064,556 and $1,039,625 for the year ended December 31, 2012 and 2011, respectively. Cash was used primarily to fund our operating losses exclusive of non-cash expenditures such as stock compensation for services and changes in the fair value of our derivative liabilities. For the year ended December 31, 2012 and 2011, operating activities were impacted by increases in our accounts payable of $1,775,489 and $300,525, increases in deferred income related to our license agreements of $720,000 and $502,500 and an increase in accrued liabilities, related party, of $378,715 and $354,207 primarily related to salaries and research fees payable to our chief executive officer and spouse, respectively. We have also paid approximately $2.1 million towards the construction and infrastructure costs for the office space where our laboratory and corporate office are located on Park Avenue in New York, NY, which space is leased by our chief executive officer.


http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9509877 page 30

Quote:
We are provided office facilities and related services by a company owned by Steven Victor, our chief executive officer, for which we paid between $10,000 to $15,000 per month. We have recorded rent and utilities expenses of $467,803 representing our portion for the year ended December 31, 2012. We have paid or accrued such rent expense since inception. On June 1, 2011, a company owned by Steven Victor, our chief executive officer, entered into a 13 year lease for new office space located at 460 Park Avenue, for which we unconditionally guaranteed any and all obligations owed under the lease to the landlord. In connection with the execution of the lease, we established a restricted cash account in the amount of approximately $650,000 to secure a line of credit to be used as a security deposit under the lease. We estimate we will pay approximtely 60% of the approximately monthly lease of $53,000 and utilities per month to sublease office space from the company owned by Dr. Victor. As of the date of the this filing herein, the Company has not finalized the sublease agreement.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9509877 page 39

Quote:
SIGNATURES

Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


INTELLICELL BIOSCIENCES, INC.


Date: September 16, 2013

By: /s/ Steven A. Victor

Name: Steven A. Victor
Title: Chief Executive Officer (Principal Executive Officer and Principal Financial Officer), and Director



Quote:
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.


SIGNATURE TITLE DATE


/s/ Steven A. Victor
Chief Executive Officer, and Director (Principal Executive Officer,

September 16, 2013
Steven A. Victor
Principal Financial and Accounting Officer)


/s/Leonard Mazur
Director
September 16, 2013 Leonard Mazur


/s/ Michael Hershman
Director
September 16, 2013 Michael Hershman


/s/ Myron Holubiak
Director
September 16, 2013 Myron Holubiak



the filings was SVFC's not Regen hence the word our & our = $$SVFC
Quote:
Rent and office administrative expenses

Included in general and administrative expenses are $96,900 and $290,700, and $104,477 and $298,396 of rent for the three and nine months ended September 30, 2013 and 2012, respectively. The office lease costs for our 460 Park Avenue location was approximately $96,900, net of a lease allocation of 40% of the lease costs to Regen Medical. The office lease and administrative services costs for the three and nine months ended September 30, 2012 was $75,000 and $150,000 provided by and at the former facility of Regen Medical, a company owned by our chief executive officer.


http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9631340

as I stated Regen's allocation of said rent is 40% & always has been as per Dr. Steven Victor himself

& btw SVFC also paid
Quote:
ITEM 2. PROPERTIES.

Our corporate offices and laboratory are located at 460 Park Avenue, 17 th Floor, New York, New York 10022. We are currently provided office facilities and related services by a company owned by Dr. Steven Victor, our chief executive officer.

Such company entered into a 13 year lease for the office space located at 460 Park Avenue for which we have unconditionally guaranteed any and all obligations owed under the lease to the landlord. In connection with the execution of the lease, we established a restricted cash account in the amount of approximately $650,000 to be used as a security deposit under the lease.



we = $$SVFC wink

Quote:
PART I

We urge you to read this entire Annual Report on Form 10-K, including the “Risk Factors” section and the financial statements and related notes included herein. As used in this Annual Report, unless context otherwise requires, the words “we,” “us”, “our,” “the Company,” “Intellicell” and “Registrant” refer to Intellicell Biosciences, Inc, including subsidiaries and predecessors, except where it is clear that the term refers to Intellicell Biosciences, Inc. Also, any reference to “common shares,” or “common stock,” refers to our common stock, par value $0.001 per share.



http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9509877

Quote:
Regen Agreement

On April 16, 2012, the Company entered into a technology license and administrative services agreement (the “Agreement”) with Regen Medical P.C., the medical practice which is owned by, and through which, our Chief Executive Officer, Dr. Steven Victor, engages in the practice of Cosmetic Dermatology (“Regen Medical”). Pursuant to the Agreement, the Company, among other things, (i) granted Regen Medical the non-exclusive and non-assignable license to utilize the Company's proprietary process and technology for its patients, (ii) granted Regen Medical a license to use a laboratory which can be used by Regen Medical for use of the Company’s proprietary process and (iii) was appointed as the exclusive manager and administrator of Regen Medical’s operations which relates to the implementation of the Company's proprietary process as well as Regen Medical’s cosmetic dermatology practice, and (iv) was appointed the sole provider of non-medical managerial, administrative and business functions for Regen Medical’s cosmetic dermatology practice. The Agreement became effective as of April 16, 2012.

In consideration for the services to be provided under the Agreement, Regen Medical is to pay the Company (i) an annual administrative fee of $600,000, payable in equal monthly installments during the term of the term of the agreement (subject to an annual increase of up to a maximum of ten percent (10%) beginning on the second anniversary of the effective date), (ii) an annual technology license fee of $120,000, payable in equal monthly installments during the term of the term of the agreement, for the use of our proprietary process (including the laboratory and the laboratory technician) and (iii) a processing fee of $1,000 for each tissue processing case that utilizes our proprietary process. The Company is also entitled to an annual performance fee during the term of either (i) $150,000, in the event total income to Regen Medical exceeds $5,500,000 or (ii) $200,000, in the event that total income to Regen Medical exceeds $7,000,000. In addition, beginning on October 16, 2013 and on each six month anniversary thereafter during the term, the Company is entitled to a share of Regen Medical’s Savings (as defined below), minus its share of any Loss (as defined below”), based upon an agreed upon base burden percentage for Regen Medical (the “Base Burden Percentage”). The Base Burden Percentage is to be calculated by dividing (a) the aggregate actual costs of Regen Medical paid by the Company during the period ending on December 31, 2011 by (b) the aggregate revenue of Regen Medical collected by the Company during the period ending on December 31, 2011; provided , however , that the Base Burden Percentage shall be recalculated on January 1, 2013 and every 12 months thereafter during the term by dividing (i) the aggregate actual costs for the Regen Medical paid by the Company during the preceding three six-month periods by (ii) the aggregate Savings or Loss is to be calculated by subtracting (a) the aggregate actual costs for the Regen Medical paid by the Company during the preceding Period from (b) an amount equal to (I) the Base Burden Percentage multiplied by (ii) the aggregate revenue of the Regen Medical collected by the Company during the preceding Period (the “Burden Amount”). If the Burden Amount exceeds the Period Actual Costs (the “Savings”) or the Period Actual Costs exceed the Burden Amount (the “Loss”), Regen Medical and the Company shall share such Savings or Loss 65% for the account of the Regen Medical and 35% for the account of the Company. The Company incurred revenue of $150,000 for the three and nine months ended September 30, 2012 under the agreements.

On August 26, 2013, the Company and Regen Medical entered into a termination and general release agreement (the “Termination Agreement”), effective December 31, 2012 (the “Effective Date”), pursuant to which the Company and Regen Medical agreed, among other things, that as of the Effective Date, (i) the Company shall forgive the $514,000 owed to the Company by Regen Medical under the Regen Medical Agreement in exchange for the exclusive right to certain open label data and other data which the Company would like to have the rights to use as empirical data or evidence of the efficacy of the Company’s proprietary process (the “Clinical Data”), (ii) the parties will take all necessary steps to enter into an agreement for the grant of a license to Regen Medical for the Company’s proprietary process as well as a license of the Clinical Data, (iii) the Regen Medical Agreement is terminated in its entirety and shall be deemed null and void and of no further force or effect and (iii) neither Company nor Regen Medical shall have any further rights or obligations under the Regen Medical Agreement. Each party also provided a general release to the other party with respect to the Regen Medical Agreement and all transactions contemplated by the Regen Medical Agreement.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9631340 page 15-16




from the most recent 10Q
Quote:
4.

Property and Equipment

The Company’s property and equipment at September 30, 2013 and December 31, 2012 consists of the following:


9/30/2013 12/31/2012

Lab equipment $206,089 $ 203,204
Leasehold Improvements 2,226,181 1,954,181
Furniture & Fixtures 463,769 459,498



http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9631340 page 11

aahh the Furniture involved in the new announced lawsuit for Default of Payment that Vic valued, himself above


START HERE. SVFC DD COMPILATION.


***Updated: 1/30/2014***


Table of Contents:

1) The Industry
2) The Company
3) The People
4) The Science
5) The Patents
6) The Due Diligence


1) The Industry


Regenerative Medicine (RM) is currently a $15 billion market and is expanding rapidly. In fact, many are calling this LARGELY UNTAPPED market "The Internet of Healthcare," and it is projected to reach $300 billion by year 2020 as patient advocacy groups demanding shift to RM proliferate worldwide (source: US Department of Health and Human Services). 1.2 million patients have been treated to date with RM products and therapies. Currently, 300 private and 50 public companies exist with $4.7 billion in total market capacity. $1.5 billion in worldwide research funding projected to $14 billion in 10 years.


2) The Company


Intellicell is a fully-reporting company currently trading on OTCQB.

The Company's Website


Synopsis:

Intellicell is an emerging leader in regenerative medicine using highly potent stromal vascular fraction cells derived from vasculature of fat tissue via uniquely efficacious technology that is patented in the United States with multiple patents pending internationally. The company is intentioned to enter the large and rapidly growing market of medical conditions where cellular therapies are far more effective than traditional techniques alone.


MOST RECENT SHARE STRUCTURE:

SHARES OUTSTANDING:1,369,825,849 as of January 28, 2014 (latest filing)

AUTHORIZED SHARES:1,500,000,000


3) The People


The CEO


Dr. Steven Victor, founder and CEO of IntelliCell has been at the forefront of clinical product and process development for over 20 years. The patent pending process that Dr. Victor has developed for IntelliCell™ has been in research for over 4 years. In addition to developing clinical products that are used nationally and internationally in the medical aesthetics field, Dr. Victor is a practicing dermatologist in New York City. He has been a sought after national figure for teaching physicians new clinical techniques worldwide for over 20 years. Dr. Victor has also been featured in national and local media as a clinical subject matter expert in regenerative medicine, medical aesthetics, and dermatology.


Board of Directors


Mr. Michael Hershman

IntelliCell BioSciences Appoints Mr. Michael Hershman as Chairman of the Board of Directors

Mr. Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. President and CEO of the Fairfax Group, a company he founded in 1983, that has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the consult of senior-level officials and/or the entities with which they do business.

More on Mr. Hershman can be found on the website of Fairfax Group by following this link.

Here is a video in which Michael Hershman is awarded Columbia Business School’s 2013 Botwinick Prize in Business Ethics.

I suppose having a renowned business ethics expert and a successful businessman with multiple governmental connections as your BOD Chairman is not a bad thing ;)


Mr. Myron Holubiak

Myron Holubiak is currently President of 1-800-Doctors, Inc. Mr. Holubiak is also Chairman of the Board of Directors of BioScrip, Inc., an infusion and home health company, and Lead Independent Director of Ventrus BioSciences, Inc. From 1998 through 2001, Mr. Holubiak was President of Roche Laboratories, Inc. and previously in his career, he co-founded and served as CEO to Emron, Inc, a strategic marketing firm serving the pharmaceutical industry, which was acquired by Dunn & Bradstreet and IMS Health in 1995. Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation.


Mr. Leonard L. Mazur

Mr. Leonard L. Mazur Co-founded Triax Pharmaceuticals, LLC and serves as its Chief Operating Officer. Mr. Mazur also Co-Founded Akrimax Pharmaceuticals in 2007. Mr. Mazur began his pharmaceutical career with Cooper Laboratories in 1971, where he served as a Product Manager for ophthalmology, dermatology and other products. He was responsible for creating and growing the business that was sold to Pierre Fabre, a French dermatology company, in 2002. In 1995, he founded Genesis Pharmaceutical, Inc., and served as its Chairman, Chief Executive Officer from 1995 to 2005 and President.


Mr. Sam Khashman

IntelliCell Biosciences Announces the Addition of Mr. Sam Khashman to Board of Directors

During the past 20 years, Mr. Khashman has successfully directed the creation and launch of 14 products and 3 companies in the healthcare, financial, and manufacturing sector. He currently serves as the President and Chief Executive Officer of Technology Partners, Inc. DBA IMAGINE Software. Mr. Khashman founded the company and created the IMAGINE practice management system that is currently used in 48 States by more than 10,000 physicians. In addition to his involvement in numerous civic and charitable organizations, Mr. Khashman serves on the board of the National Chamber Foundation, the public policy think tank of the U.S. Chamber of Commerce in Washington D.C.


Medical Advisory Board


Dr. James Andrews

IntelliCell BioSciences Inc. Announces James R. Andrews, M.D. Has Joined Its Medical Advisory Board

Doctor James Andrews is one of the founding members of Andrews Sports Medicine and Orthopaedic Center in Birmingham, Alabama. He is also a founder of the American Sports Medicine Institute (ASMI) a non-profit institute dedicated to injury prevention, education and research in orthopaedics and sports medicine. This foundation is recognized as one of the world’s leaders in this field. Doctor Andrews is internationally known and recognized for his skills as an orthopaedic surgeon as well as his scientific and clinic research contributions in knee, shoulder and elbow injury prevention and treatment. In addition, he has made major presentations on every continent, and has authored numerous scientific articles and books.

Everything you ever wanted to know about Dr. Andrews and how prominent he is in the athletic community can be found following this link. Credit: Sibware

A list of athletic celebrities treated by Dr. Andrews as of 5 years ago can be found following this link.

Could some of his NEW celebrity patients have been treated with the help of Intellicell’s technology, but not yet publicized?


Dr. Joshua Hackel.

Another member of Andrews Institute on Intellicell’s board of medical advisors is Dr. Joshua Hackel. His profile information can be found here.


Dr. Sydney Coleman

You can read more about Dr. Coleman's extensive stem cell projects funded by the Department of Defense through the Office of the Assistant Secretary of Defense for Health Affairs in this post by lee13.


Note that these fantastic people are just part of the group currently working to move Intellicell’s technology forward. Complete corporate profile for the company can be found following this link. Just Google some of the names not mentioned in this post to see that Intellicell is associated with crème de la crème of medical and scientific communities.


4) The Science


According to this PR, an antibody flow cytometry study of IntelliCell's technology was performed by Millipore, a division of Merck (NYSE: MRK) and found that:

"IntelliCell's proprietary technology yield an average of 10 times (10X) the number of SVF cells containing adult adipose stem cells from less fat (only 2 oz) than that which the Company believes is used by any of its present competition utilizing enzymes in their process. The study also showed that IntelliCells™ contain all of the viable cells that are manufactured by competing technologies that use enzymatic digestion."

Click on this link to see the original figures from the Millipore studies of Intellicells. Credit: cazual

The following image presents cell culturing report using Intellicell’s technology:





Moreover, it is because no enzymes are necessary in Intellicell’s process that they are the only public commercial stem cell company in the United States to meet FDA Rule 361 exemption. Under the FDA’s Rule 361, IntelliCells is currently authorized to commercially sell its SVF stem cells in the U.S. The PR announcing the most recent FDA inspection of the company’s flagship lab can be found here. The copy of the FDA report can be obtained by following this link. Note that most of the observations cited in the report are minor and can be corrected easily. When the FDA spends four days in ANY lab, they WILL find something – it’s just the way the game goes.

Additionaly, the company previously announced that “it has received the results of its independent laboratory audit by Biologic Consultant Group and the audit showed that the new lab at 460 Park Avenue, New York, NY was cGTP compliant.”

Futhermore, as announced here, Intellicell “has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product.”

Intellicell Biosciences wins key listing from the FDA

Finally, according to this news release, Intellicell “has been granted a Research Tissue Banking License by the New York State Department of Health.” Which will now allow the company to engage in “the development of autologous and allogenic stromal vascular fraction tissue for researchers around the world.”

A great summary of Intellicell’s technology as compared to current competitors can be found on page 19 of the company’s most recent investor presentation. The visual comparison is presented below:









A list of Intellicell’s current human clinical trials, as officially reported by the company in the latest investor presentation can be found in this post by lee13.

Here is an additional link to a prospective pilot study using Intellicell’s technology on the successful clinical application of SVFC on the gingival recession defects.

And an additional link to a planned study using Intellicell’s technology for Diabetic Foot Ulcers.


Finally, following is a collection links to official progress reports by the company in regards to successful use of technology for some of the most prominent conditions in today’s healthcare.


IntelliCell Biosciences' Cellular Therapy Treatment Yields Positive Results in Multiple Sclerosis Patients

IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis

IntelliCell Biosciences Stem Cells Used to Successfully Treat Bell's Palsy and Type I Diabetes Patient

Moreover, Dr. Babak Azizzadeh, one of the more prominent doctors in the nation, certainly a superstar in his field, acknowledges the Intellicell’s success.

Babak Azizzadeh, MD, FACS, Director of the Facial Paralysis Institute, comments on the recent treatment of a Bell’s palsy patient with stromal vascular fraction cells.


5) The Patents


IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology

You can find the U.S. patent overview here.

But not only is Intellicell’s technology fully patented in the United States, there are also multiple international patent applications that are pending. Links to European, Australian, Canadian, Thailand and Korean patents can be found in cazual’s post following this link.

It is clear that these patents when granted will open up a whole world of unique revenue-generating possibilities, especially in the countries and jurisdictions where stem cell laws and regulations are much more progressive than in the United States.

And the most important patent of them all, the European one, is one final step away from being granted! The news could come any day now! See the image below (courtesy of Sir Francelote)







6) The Due Diligence


In December 2013, Dr. Victor returned back from the business trip to a world-renowned hospital in Korea that is actively engaged in stem cell treatments of international celebrities. Related DD and picture confirmation of the trip can be found in this post.

Another impressive picture from the CEO's Korean trip can be seen here. (Source: Dr. Victor's Twitter Account)

More amazing pictures from the Korean trip can be found in this post by click5.

Here is a list of medical staff from CHAUM Global Stem Cell Clinical Trials Center.

Find the pictures of Intellicell's flagship clinic by following this link. Credit: Sir Francelote

Stervc’s comparison and contrast between SVFC and their main competitor CYTX can be seen here.

Stervc's post on SVFC & Bereskin & Parr LLP connection can be found by following this link.

Some notes on why Intellicell's process without enzymes is superior to that of CYTX, can be read in this post and also here.

You can read my thoughts on why Intellicell's debt is not all that bad by following this link.

The company's business plan is discussed here.

Forbes article discussing Intellicell's advantage.
“A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.”

Some calculation and comparison of cell yield from Intellicell and their competitors can be found in this post.

As shown here some of the insiders do believe in this company enough to trust it with couple hundred thousand dollars out of their own pockets.

Here is a link to a post by iHub member LJ Silver about a mystery investor who was willing to provide Intellicell with $500,000 of cold, hard cash.

Sir Francelote provides some quick DD in regards to where Intellicell stands against its competitors in this post.

lee13 shares some good thoughts on the likelihood of a buyout in this post.

Even if the FDA fails to support stem cell industry in the US – multiple international patents (See “The Patents”) will open up countless business possibilities abroad, where regulations in regards to human use of stem cells is much more progressive. And let’s not forget that Intellicell can still explore and capitalize upon less regulated US markets in cosmetics and veterinarian care. In fact, the company has already investigated veterinary market as per this PR.

Let’s not forget that the CEO is NOT getting paid until Intellicell is generating some significant revenues as explained by TheSkunk.

If you ever wondered about the reasons why Intellicell used to trade at $4 but is now a penny stock, you can read some thoughts on this matter that are posted right here.

You can read about Intellicell's relationship with ReGen Clinic by following this link.


MUST-VISIT LINKS


Most Recent Investor Presentation (February 2013)

Most Recent (7.11.2013) Intellicell's CEO interview (Audio)

Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process (July 8, 2013)

The CEO’s Twitter Account


Best of luck!

i.t.m.d.



 

 


 

 

INTELLICELL BIOSCIENCES, INC.



About IntelliCell BioSciences, Inc.

IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC). VFC is also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. VFC type cells are in research projects and in clinical trials around the world.

IntelliCell was formed to take a leading role and harmonize the interests of all the stakeholder communities in the rapidly expanding regenerative medicine field. IntelliCell is fully committed to an ethical and supportive role in providing the tools to physicians and patients to fight some of the most serious disease conditions with very high levels of unmet clinical needs.

The VFC cells that are being processed by IntelliCell are known as autologous cells. That is the donor of cells and the recipient of the cells are the same person. IntelliCell is unique as it does not use any chemicals or biological agents such as collagenese in its proprietary and patent pending process. The Company has developed a novel ultrasound process to assist the laboratory in the preparation of the VFC cells. In a process similar to the acquisition of autologous stem cells from bone marrow aspirate, the IntelliCell VFC cells are being given to physicians working in the field of regenerative medicine.



 

 


                                                             SVFC where the money has gone, with quotes, links to filings w/ page numbers & Steven Victor's signature attesting to it all...for complete verification
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94898759




 

 

LATEST SHAREHOLDER LETTER
 

NEW YORK, NY--(Marketwired - Dec 10, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, provides shareholder update.

 

Dear Valued Shareholders,

On behalf of myself, the Board of Directors and the entire IntelliCell team, I would like to let you know that we are pleased with the growth initiatives that we have accomplished since our initial shareholder letter.

Now is an important and exciting time for IntelliCell Biosciences. We have continued to improve our competitive position in the regenerative medicine field and I believe we have never been stronger or better positioned for future growth. The worldwide regenerative medicine market is being driven by previously unseen treatments and procedures that are improving the quality of life of patients around the world and we firmly believe that we will emerge as one of the leaders in this industry.

The Company has been executing on our strategic plan and business priorities this year. We have made advancements in our technology and have filed patents around the world for our proprietary regenerative medical solutions. I am encouraged by the expanding market presence of IntelliCell Biosciences and the escalating acceptance of the Company's products and solutions within the medical, scientific and investment community. Additionally, we continue to work hard at improving our balance sheet and financial position, in order to have the necessary resources to take advantage of our growth opportunities. Because of all these accomplishments, I believe we are better positioned than ever for growth.

We have focused primarily on three strategic initiatives, Growth, Leverage, and Financial Strength, in order to improve the overall standing of the company.

Growth: We will continue to grow and supply our cellular product to physicians to treat their patients with clinical needs. We intend to be a major provider of minimally manipulated stromal vascular fraction cells SVFCs for autologous use to physicians and achieve exciting clinical results that improve the quality of life for their patients.

Leverage: We are leveraging our scale and best practices to create a cost-effect business model that increases our competitive advantage over our industry peers. Our intent is to open 3 additional facilities in 3 states in the next 12 months. Once the model is perfected, we will roll out additional facilities at a more aggressive pace. As the regenerative medical market expands, we intend to be the most recognized name in the industry.

Financial Strength: We have a goal of improving our balance sheet and income statement in order to deliver strong shareholder returns. Currently we are enacting a plan to remove all debt from our balance sheet. Going forward, it is our intent to use equity capital for the advancement of our company. Believing that IntelliCell Biosciences stock is undervalued, I will be converting a portion of my debt into shares and will continue this practice going forward. These measures will enable us to continue implementing our business and open new Cellular Labs in hospitals and ambulatory surgical centers that will significantly increase our revenues.

We are committed to advance the regenerative medicine field. This will enable us to become more productive, reliable and cost effective than ever before. IntelliCell's physician partners have informed us that we are well-aligned with their strategic intentions, and their clinical and business priorities. These are the key priorities that will ensure IntelliCell's future success.

As many of you know, our technology is new and cutting edge and requires acceptance by the marketplace and the regulators. We will remain aggressive in our efforts to overcome industry obstacles so that our medical solutions can serve as the industry standard. The Company has successfully developed advanced medical technologies, most notably its patented process of isolating SVFCs from adipose (fat) tissue using a mechanical technique, exclusive to the industry of regenerative medicine, now being used by physicians to treat patients with previously unmet clinical needs.

Management firmly believes that regenerative medicine is the future of medicine and we intend to aggressively expand our market footprint in order to solidify our position as the leader in the field. We would like to express our gratitude to our loyal global customer base and we are grateful to our shareholders for their continued support and ownership in our company. As CEO and Founder of IntelliCell, my paramount responsibility is to enhance shareholder value. I take immense pride in the success of this company to date and remain committed to delivering the best products and services possible to increase market presence in the future.

We at IntelliCell Biosciences are confident that our vision and goals will be achieved.

Sincerely,

Dr. Steven Victor
Chief Executive Officer
IntelliCell Biosciences, Inc.



Link to the most recent FDA Inspection Form 483 issued on 06/06/2013 http://www.ipscell.com/wp-content/uploads/2013/08/Intellicell-483_2013.pdf



RELEVANT LINKS


DD COMPILATION (January 30, 2014)
 

http://www.intellicellbiosciences.com


https://twitter.com/stevenvictormd
 




   

 

DAILY CHART

PostSubject
#62715  Sticky Note SVFC $$$$ Updated AWESOME DD for newbies:) cazual 04/16/14 10:42:07 PM
#57710  Sticky Note START HERE. SVFC DD COMPILATION. i.t.m.d. 03/12/14 01:47:07 PM
#54605  Sticky Note $$SVFC where the money has gone, with quotes, BigBadWolf 02/22/14 07:36:34 AM
#44513  Sticky Note Updated SVFC & CYTX-Compare & Contrast… stervc 01/23/14 04:01:38 AM
#62933   A penny break is coming! seanmurphymusic 04/18/14 02:06:14 AM
#62932   Wow, you must be REALLY depressed. Oh well, Marketboy 04/18/14 01:17:54 AM
#62931   The only reason I can convince myself of UncleRico 04/18/14 12:33:01 AM
#62930   I hope it works out in your favor,i'm skills3 04/17/14 11:32:50 PM
#62929   I believe!!!!!!!! ALL Longs will be tested the bld 04/17/14 11:23:09 PM
#62928   I hope it holds until Tuesday when i roller150 04/17/14 11:11:07 PM
#62927   Oh yes we are going to go over skills3 04/17/14 10:50:53 PM
#62926   Another nickel;) Sal70 04/17/14 10:47:08 PM
#62925   We all thought ( hoped ) SVFC would've Toeinmouth 04/17/14 10:47:06 PM
#62924   HA Ha,,,you are not alone,i've been in since skills3 04/17/14 10:42:34 PM
#62923   Ok.... All u regular posters.... Lol...I think big kaw_baby 04/17/14 10:10:52 PM
#62922   Ok.... All u regular posters.... Lol...I think big kaw_baby 04/17/14 10:10:51 PM
#62921   Margin man I didn't read this, sorry. roller150 04/17/14 09:07:09 PM
#62920   Margin an, market closed tomorrow. roller150 04/17/14 09:04:03 PM
#62919   ;) Sal70 04/17/14 08:55:54 PM
#62918   I sure hope you guys got more today.....DA MOOOOOOOOONNNNN skills3 04/17/14 08:50:01 PM
#62917   Damn! Monday it is then! ;) JLHammer 04/17/14 08:47:23 PM
#62916   Yep I was joking. Hence the ;) face MarginMan 04/17/14 08:46:31 PM
#62915   Are we closed tomorrow? JLHammer 04/17/14 08:45:56 PM
#62914   Svfc to da mooooooon. Any day now. MarginMan 04/17/14 08:45:03 PM
#62913   Why don't they attend? Venture_Cap 04/17/14 08:39:14 PM
#62912   Another failed attempt to break through the .0048-.005 Ionthefuture 04/17/14 08:10:09 PM
#62911   It will happen and it will be played rockykoda 04/17/14 07:58:52 PM
#62910   LOL skills3 04/17/14 07:07:58 PM
#62909   SVFC will go up when it is ready! Sal70 04/17/14 06:56:47 PM
#62906   Thank You! Wish I could send my 'burgers' rockykoda 04/17/14 04:47:43 PM
#62904   GOOD DAY TODAY!! Toeinmouth 04/17/14 04:38:13 PM
#62903   Who knows, maybe that is the reason its roller150 04/17/14 04:20:40 PM
#62902   SVFC -- a technological breakthrough that will benefit Ustmel 04/17/14 04:15:45 PM
#62901   chart keeps getting better!!!!! Toeinmouth 04/17/14 04:14:20 PM
#62900   Caz, so now what, we have to wait roller150 04/17/14 04:13:57 PM
#62899   This rodeo about to get really wild... Several gempicker 04/17/14 04:12:22 PM
#62897   Heee haw!!! Alrighty then!!! canitocano73 04/17/14 04:10:07 PM
#62895   LOL I don't know what you said, but Toeinmouth 04/17/14 04:06:51 PM
#62894   There's much more to this story than we Venture_Cap 04/17/14 04:06:50 PM
#62892   Looking for truth and facts???...this nice green close cazual 04/17/14 04:03:05 PM
#62891   yep & it only took a 1000 share BigBadWolf 04/17/14 04:02:38 PM
#62889   Van Gogh has his brush out today! Pennies Make Cents 04/17/14 04:00:53 PM
#62888   GREAT CLOSE!!!! Toeinmouth 04/17/14 04:00:41 PM
#62886   Closed STRONG! Good job $VFC pioneers! Ricktheslick 04/17/14 04:00:20 PM
#62885   Green close!! One day closer!! Scottieboom 04/17/14 03:59:08 PM
#62884   * SVFC - look at the RIDICULOUS attempts Gannicus 04/17/14 03:58:38 PM
#62879   I'll agree that some of the DD has cazual 04/17/14 03:48:24 PM
#62874   Thorough DD is working hard to find & BigBadWolf 04/17/14 03:41:02 PM
#62873   You're welcome and me neither! SVFC$$$$ trebeg 04/17/14 03:40:32 PM
#62871   That doesn't make any sense. Thorough DD IS trebeg 04/17/14 03:39:00 PM
#62870   Trebeg, Thank you. I am not giving up. LarryC213 04/17/14 03:35:04 PM
#62869   No need for any to work hard w/ BigBadWolf 04/17/14 03:34:51 PM
#62866   Got more today,,,,next week will be good for skills3 04/17/14 03:31:35 PM
#62865   capitulation is a bitch when retail hold huge positions... gempicker 04/17/14 03:31:30 PM
PostSubject